Kiromic BioPharma, Inc. (KRBP) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kiromic BioPharma, Inc. (KRBP) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Kiromic BioPharma, Inc. (KRBP) Resumen de Asistencia Médica y Tuberías
Kiromic BioPharma, Inc. is an AI-driven biotechnology company specializing in allogeneic Gamma Delta T cell therapies targeting solid tumors. Their pipeline includes ALEXIS-ISO-1 and ALEXIS-PRO-1, novel cell therapies designed to enhance the natural potency of Gamma Delta T cells. The company operates in the competitive biotechnology sector.
Tesis de Inversión
Kiromic BioPharma's investment thesis centers on its innovative approach to cancer treatment using allogeneic Gamma Delta T cell therapies. The company's focus on solid tumors, a significant unmet medical need, presents a substantial market opportunity. Key value drivers include the successful development and commercialization of ALEXIS-ISO-1 and ALEXIS-PRO-1. Growth catalysts include advancing these product candidates through clinical trials and securing partnerships for manufacturing and distribution. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $0.00B and a P/E ratio of -0.17, the company's valuation reflects its early-stage development.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Kiromic BioPharma is focused on developing allogeneic Gamma Delta T cell therapies for solid tumors.
- Lead product candidates include ALEXIS-ISO-1 targeting Isomesothelin and ALEXIS-PRO-1 targeting PD-L1.
- The company leverages artificial intelligence to enhance its cell therapy development process.
- Kiromic has established strategic alliances and licensing agreements to support its research and development efforts.
- The company's therapies aim to exploit the natural potency of Gamma Delta T cells to improve cancer treatment outcomes.
Competidores y Pares
Fortalezas
- Innovative AI-driven platform for cell therapy development.
- Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
- Strategic alliances and licensing agreements.
- Experienced management team with expertise in cell therapy and immuno-oncology.
Debilidades
- Early-stage development with no approved products.
- Limited financial resources.
- High risk of clinical trial failures.
- Dependence on strategic alliances for manufacturing and distribution.
Catalizadores
- Upcoming: Clinical trial results for ALEXIS-ISO-1 in solid tumors.
- Upcoming: Clinical trial results for ALEXIS-PRO-1 in solid tumors.
- Ongoing: Expansion of Kiromic's AI-driven platform for new cell therapy targets.
- Ongoing: Strategic partnerships for manufacturing and distribution.
- Ongoing: Advancements in Gamma Delta T cell therapy technology.
Riesgos
- Potential: Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.
- Potential: Regulatory hurdles and delays in obtaining FDA approval.
- Potential: Competition from established pharmaceutical companies and emerging biotech firms.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on strategic alliances for manufacturing and distribution.
Oportunidades de crecimiento
- Advancing ALEXIS-ISO-1 through clinical trials represents a significant growth opportunity. Isomesothelin is overexpressed in several solid tumors, including mesothelioma, ovarian cancer, and lung cancer. Positive clinical data demonstrating the safety and efficacy of ALEXIS-ISO-1 could lead to accelerated regulatory approval and commercialization. The market for mesothelioma treatment alone is projected to reach billions of dollars by 2030, offering a substantial revenue opportunity for Kiromic.
- The development of ALEXIS-PRO-1 targeting PD-L1 presents another key growth avenue. PD-L1 is a well-validated target in immuno-oncology, and ALEXIS-PRO-1 has the potential to address a broad range of solid tumors. Successful clinical trials could position ALEXIS-PRO-1 as a competitive alternative to existing PD-1/PD-L1 inhibitors. The global market for PD-1/PD-L1 inhibitors is estimated to be over $40 billion, indicating the significant commercial potential of ALEXIS-PRO-1.
- Expanding the application of Kiromic's AI-driven platform to discover and develop new cell therapies represents a long-term growth opportunity. The company's artificial intelligence capabilities can be leveraged to identify novel targets and design more effective cell therapies. This platform approach could lead to a pipeline of innovative products addressing a wide range of cancers and other diseases. The market for AI-driven drug discovery is projected to experience rapid growth in the coming years.
- Establishing strategic partnerships with pharmaceutical companies for manufacturing and distribution can accelerate the commercialization of Kiromic's products. Partnering with established players can provide access to resources and expertise that are critical for navigating the complex regulatory landscape and reaching a broader patient population. These partnerships can also generate upfront payments and milestone payments, providing additional funding for research and development.
- Exploring the potential of Gamma Delta T cell therapies in combination with other cancer treatments, such as chemotherapy and radiation therapy, represents a promising growth area. Combination therapies can potentially enhance the efficacy of existing treatments and improve patient outcomes. Kiromic can conduct clinical trials to evaluate the safety and efficacy of its cell therapies in combination with other modalities. Positive results could lead to new treatment paradigms and expanded market opportunities.
Oportunidades
- Advancing ALEXIS-ISO-1 and ALEXIS-PRO-1 through clinical trials.
- Expanding the application of its AI-driven platform to discover new cell therapies.
- Establishing partnerships with pharmaceutical companies for commercialization.
- Exploring combination therapies with other cancer treatments.
Amenazas
- Competition from established pharmaceutical companies and emerging biotech firms.
- Regulatory hurdles and delays in obtaining FDA approval.
- Changes in the regulatory landscape for cell therapies.
- Unfavorable clinical trial results.
Ventajas competitivas
- Proprietary AI-driven platform for target identification and cell therapy design.
- Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
- Intellectual property protection for its cell therapy products and technologies.
- Strategic alliances and licensing agreements that provide access to resources and expertise.
Acerca de KRBP
Founded in 2006 and headquartered in Houston, Texas, Kiromic BioPharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company focused on developing innovative cancer treatments. The company leverages the natural potency of Gamma Delta T cells to target solid tumors, aiming to create more effective and accessible therapies. Kiromic's lead product candidates include ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy targeting PD-L1. These therapies are designed to overcome the limitations of traditional cancer treatments by harnessing the unique properties of Gamma Delta T cells. Kiromic has established license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has a strategic alliance agreement with Leon Office (H.K.) Ltd. Kiromic BioPharma, Inc. was formerly known as Kiromic, Inc. and changed its name in December 2019, reflecting its commitment to advancing biopharmaceutical solutions.
Qué hacen
- Develops allogeneic Gamma Delta T cell therapies for solid tumors.
- Utilizes artificial intelligence to identify and validate therapeutic targets.
- Conducts preclinical and clinical research to evaluate the safety and efficacy of its therapies.
- Manufactures cell therapy products for clinical trials.
- Seeks regulatory approval for its therapies from the FDA and other regulatory agencies.
- Establishes strategic partnerships for manufacturing, distribution, and commercialization.
Modelo de Negocio
- Develops and licenses allogeneic Gamma Delta T cell therapies.
- Generates revenue through strategic alliances and licensing agreements.
- May generate future revenue through product sales upon regulatory approval.
- Focuses on research and development of innovative cancer treatments.
Contexto de la Industria
Kiromic BioPharma operates within the rapidly evolving biotechnology industry, specifically in the cell therapy and immuno-oncology sectors. The market for cell therapies is experiencing significant growth, driven by advancements in genetic engineering and a deeper understanding of the immune system's role in fighting cancer. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing similar therapies. Kiromic's focus on allogeneic Gamma Delta T cells differentiates it from companies primarily focused on alpha-beta T cell therapies, potentially offering advantages in terms of scalability and safety.
Clientes Clave
- Patients with solid tumors who are candidates for cell therapy.
- Hospitals and cancer centers that administer cell therapies.
- Pharmaceutical companies that may partner with Kiromic for commercialization.
- Research institutions that collaborate with Kiromic on research and development.
Finanzas
Gráfico e información
Precio de la acción de Kiromic BioPharma, Inc. (KRBP): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para KRBP.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para KRBP.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para KRBP.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de KRBP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Pietro Bersani CPA,
CEO
Pietro Bersani is the Chief Executive Officer of Kiromic Biopharma. His background includes experience as a Certified Public Accountant. His expertise lies in financial management and strategic leadership within the biotechnology sector. He brings a wealth of knowledge in corporate finance and accounting to Kiromic Biopharma. His previous roles have equipped him with the skills necessary to navigate the complexities of the pharmaceutical industry.
Historial: Since becoming CEO, Pietro Bersani has focused on advancing Kiromic's pipeline of allogeneic Gamma Delta T cell therapies. He has overseen the company's research and development efforts, strategic alliances, and financial operations. Key milestones under his leadership include progressing ALEXIS-ISO-1 and ALEXIS-PRO-1 through preclinical development and initiating clinical trials. He is managing 44 employees.
Información del mercado OTC de KRBP
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kiromic BioPharma may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited operating history, be in financial distress, or have chosen not to comply with higher reporting standards. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Assess the company's internal controls and risk management practices.
- Company has a functioning website and contact information.
- Company has a physical headquarters and employees.
- Company has strategic alliances and licensing agreements.
- Company has a board of directors and management team.
- Company is actively engaged in research and development activities.
Lo Que los Inversores Preguntan Sobre Kiromic BioPharma, Inc. (KRBP)
¿Cuáles son los factores clave para evaluar KRBP?
Kiromic BioPharma, Inc. (KRBP) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Innovative AI-driven platform for cell therapy development.. Riesgo principal a monitorear: Potential: Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de KRBP?
KRBP actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de KRBP?
Los precios de KRBP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre KRBP?
La cobertura de analistas para KRBP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en KRBP?
Las categorías de riesgo para KRBP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de KRBP?
La relación P/E para KRBP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está KRBP sobrevalorada o infravalorada?
Determinar si Kiromic BioPharma, Inc. (KRBP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de KRBP?
Kiromic BioPharma, Inc. (KRBP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be subject to change.
- AI analysis is pending for KRBP.